Immunovant, Inc. research snapshot
IMVT AI stock analysis currently views Immunovant as a clinical-stage immunology company with a potentially broad IMVT-1402 platform, strong cash after its 2025 financing, and no approved product revenue yet. At the July 12, 2026 research cutoff, the latest verified close was $39.71 on July 10 and the market capitalization was about $8.15 billion, calculated from 205.308917 million shares. FY2026 revenue was $0, net loss was $505.6 million, operating cash use was $407.3 million, and cash was $902.1 million at March 31, 2026. Positive difficult-to-treat rheumatoid arthritis data support the upside case, while the failed batoclimab thyroid eye disease studies, dependence on IMVT-1402, future dilution, and a valuation far above current book value keep investment certainty low. This page is informational research only and is not investment advice.
Current price
$39.71
Market cap
$8.15 billion calculated market capitalization
AI score
52 / 100
Rating
Strong pipeline evidence, but clinical, financing, and valuation risk remain high
Trend status
Above the 50-day and 200-day averages, with RSI in overbought territory
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Immunovant has a focused anti-FcRn platform and several large autoimmune indications, but the business has not yet demonstrated product revenue or commercial execution. | Medium |
| Moat | Potential advantages include clinical data, FcRn expertise, patents, regulatory know-how, and Roivant scale. The moat is unproven and depends on approval, differentiation, and licensed rights. | Medium-low |
| Management | Eric Venker combines clinical and operating experience with Roivant oversight. Roivant held about 55.2% of voting power as of May 14, 2026, improving strategic support but creating controlled-company governance risk. | Medium-high |
| Financial trend | FY2026 net loss widened to $505.6 million and operating cash use reached $407.3 million. Cash increased after financing, but the company remains pre-revenue and cash-burning. | High for reported data |
| Valuation | At about $8.15 billion of calculated market value, 9.5x book value, and no meaningful PE or PS ratio, the price depends on future clinical and commercial value rather than current earnings. | High for valuation limits |
| Technical trend | The stock was above its reported 50-day average of $32.63 and 200-day average of $26.08, but RSI at 73.64 indicated an extended short-term move. | Medium-high |
| Risk level | Risk is high because a single lead asset drives the thesis, clinical and regulatory outcomes are uncertain, cash burn is material, and equity financing can dilute holders. | High |
| AI confidence | Confidence is strongest for historical filings, cash, losses, share count, trial milestones, and technical inputs. It is low for future returns and approval probabilities. | Medium-high for facts |
| Investment certainty | Investment certainty is low. The platform may create substantial value if IMVT-1402 succeeds, but the current price already discounts meaningful future progress. | Low |
IMVT AI stock forecast
The IMVT AI stock forecast uses conditional price bands rather than a fixed target. A PE model is not decision-useful while revenue is zero and EPS is negative, so these scenarios are tied to clinical confirmation, regulatory progress, potential commercialization, cash runway, and dilution. They are research ranges, not promises or personalized recommendations.
$55 to $75
More likely if the D2T RA program confirms its early signal, the CLE readout is constructive, GD and MG registrational trials support approval, IMVT-1402 reaches launch with useful pricing and reimbursement, and financing is manageable.
$25 to $50
More likely if the pipeline advances but approval timing remains uncertain, cash funds the next milestones, operating losses continue, and investors value Immunovant on probability-adjusted pipeline progress rather than current earnings.
$10 to $22
More likely if randomized or registrational data disappoint, regulators delay or reject an indication, safety or manufacturing issues emerge, cash needs require unfavorable financing, or the market reduces its valuation of pre-revenue biotech assets.
IMVT AI technical analysis
IMVT AI technical analysis uses the July 10, 2026 close and the latest StockAnalysis statistics snapshot reviewed on July 12. The price was above both major moving averages, but RSI was above 70 and the stock was near its 52-week high. This static page does not fetch live market data, so confirm every level on a current chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $39.71 | Latest verified close on July 10, 2026, used for the July 12 research cutoff. |
| Near support | $37 to $38 | A recent planning zone below the July 10 close. A failed hold here would weaken the immediate breakout structure. |
| 50-day moving average | $32.63 | StockAnalysis snapshot reviewed July 12, 2026. A close below this area would weaken the near-term trend. |
| Secondary support | $26 to $27 | Planning zone around the reported 200-day moving average of $26.08. |
| Near resistance | $41 to $42 | The reported 52-week high was $41.23. A sustained close above it would require continued catalyst support and healthy volume. |
| Momentum | RSI 73.64 | The latest reported RSI was above the commonly watched 70 threshold, which signals an extended move rather than a guaranteed reversal. |
| Volume | 1.71 million shares average over 20 days | A breakout is more credible when volume expands above the recent average and the move is not driven by a single headline. |
| Volatility | $14.32 to $41.23 52-week range; 9.42% short interest | The wide range and event-driven biotech profile can produce fast gaps around clinical and regulatory news. |
| Invalidation levels | Close below $32.63, then $26.08 | A close below the 50-day area weakens the near-term trend. A break below the 200-day area challenges the longer trend and should trigger a thesis review. |
IMVT AI trading strategy
The IMVT AI trading strategy is a rules-based research framework, not personalized advice. It combines price confirmation with trial data, regulatory timing, cash use, financing, and share count because technical signals alone can fail around biotech catalysts.
Treat a sustained close above $41.23 as technically stronger only if volume expands and there is no negative change in the IMVT-1402 clinical or regulatory thesis.
A failed breakout or close below the $37 to $38 planning zone reduces confidence. A close below $32.63 is a stricter trend invalidation signal.
A pullback toward the 50-day area can be studied only if upcoming data, cash runway, and trial execution remain intact. Compare price stabilization with the next company update before drawing a conclusion.
Do not average down solely because the stock is below a recent high. Reassess the clinical probability, financing terms, and maximum acceptable loss first.
Track D2T RA updates and CLE data expected in the second half of 2026, GD and MG data expected in 2027, cash use, new financing, share count, regulatory feedback, and competitor FcRn data.
Binary events can gap through any stop. Use position sizing and event exposure limits that match the possibility of a rapid loss.
Investment research summary
Immunovant is developing IMVT-1402, an anti-FcRn antibody intended to reduce pathogenic IgG activity across autoimmune diseases. Customers would ultimately pay for a safer, effective, convenient therapy, but that value is not yet reflected in product revenue because no candidate has received marketing approval.
The possible moat combines FcRn biology, clinical evidence, patents, trial execution, regulatory learning, manufacturing relationships, and Roivant infrastructure. The company licenses core rights from HanAll, and competitors can pursue the same mechanism, so the moat remains conditional rather than established.
The thesis can fail if randomized data do not reproduce early signals, safety or immunogenicity limits dosing, regulators require more studies, physicians prefer competing FcRn therapies, commercial pricing is weak, or cash burn forces dilution before value inflection.
CEO Eric Venker brings medical and operating experience and also serves as Roivant president. Roivant had about 55.2% of voting power as of May 14, 2026 and participated in the December 2025 financing. That support can improve capital access and execution, while the controlled-company structure creates minority-holder governance risk.
Autoimmune disease treatment is a durable medical trend with large unmet needs, and FcRn inhibition is a validated therapeutic approach. The opportunity is crowded, approval is indication-specific, and the eventual market depends on clinical differentiation, reimbursement, administration burden, and safety.
At a calculated market capitalization of about $8.15 billion against zero FY2026 revenue, $902.1 million of cash, negative EPS, and negative free cash flow, the stock price implies substantial future success. The 9.5x book value multiple is not a margin of safety when book value mainly reflects cash that will be consumed by development.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| IMVT price | $39.71, July 10, 2026 close | StockAnalysis forecast page | July 12, 2026 |
| Calculated market capitalization | $8.15 billion, calculated as $39.71 x 205.308917 million shares; financial_rigor.py variance 0.00% against $8,152.82 million | Immunovant 10-K and financial_rigor.py | July 12, 2026 |
| Shares outstanding | 205.308917 million as of May 14, 2026; 203.940353 million at March 31, 2026 | Immunovant FY2026 Form 10-K | July 12, 2026 |
| FY2026 revenue | $0 million; the company has not generated revenue to date | Immunovant 10-K and Macrotrends | July 12, 2026 |
| FY2026 loss and R&D expense | $505.61 million net loss and $456.66 million R&D expense | Immunovant FY2026 earnings release and StockAnalysis | July 12, 2026 |
| Cash and liabilities | $902.11 million cash and cash equivalents, $104.42 million total liabilities at March 31, 2026 | Immunovant FY2026 earnings release and StockAnalysis | July 12, 2026 |
| Operating cash use and free cash flow | $407.31 million operating cash use and approximately $407.32 million negative free cash flow in FY2026 | Immunovant 10-K and StockAnalysis | July 12, 2026 |
| IMVT-1402 D2T RA signal | Week 16 ACR20 72.7%, ACR50 54.5%, and ACR70 35.8% in an open-label period | Immunovant May 20, 2026 corporate update | July 12, 2026 |
| Batoclimab TED outcome | Both Phase 3 thyroid eye disease studies missed their primary endpoint; development was discontinued | Immunovant May 20, 2026 corporate update | July 12, 2026 |
| Roivant control | Approximately 55.2% of voting power as of May 14, 2026 | Immunovant FY2026 Form 10-K | July 12, 2026 |
| Technical inputs | 50-day MA $32.63, 200-day MA $26.08, RSI 73.64, 20-day average volume 1.71 million, short interest 9.42% | StockAnalysis statistics | July 12, 2026 |
| Analyst context | 18 analysts: average target $46, low $24, high $66; this is not the page forecast | StockAnalysis forecast page | July 12, 2026 |
This IMVT AI stock analysis page is an informational research tool only. It is not investment advice, financial advice, tax advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on public filings, quote snapshots, technical data, clinical updates, and third-party sources reviewed through July 12, 2026. They may be wrong, incomplete, or outdated after new earnings, clinical data, regulatory decisions, financing, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
